



How CROs Can Add Value To The Development of Drugs in Rare Diseases

Lisa Dilworth

Vice President, Rare, Orphan, and Pediatrics

24Feb2020

Rare Disease Challenges



Finding Patients



Lack of Validated Outcome Measures



Disease Burden



Lack of Global Standard of Care Consensus



Cross-border Enrollment Patient Travel



Caring for the Care Circle



Everchanging Regulations



Multi-disciplinary Care


Accelerating Rare Disease Drug Development



The convergence of experience and expertise are critical in order to deliver your program on-time and on-budget!

Medical Informatics:

- Claims data
- Competitive Landscape analysis
- Investigator Selection
- Electronic medical records



- Study design and end point expertise
- Patient-centric protocols
- Ongoing support

- Reducing the study burden
- Understanding diagnostic odyssey
- Sequencing of the visit



Lisa Dilworth, BS, MS
Lisa.dilworth@synteract.com

synteract.com